1Buonaguro L, Petrizzo A, Tornesello ML, et al. Translating tumor antigens into cancer vaccines[J]. Clin Vaccine Immunol, 2011, 18(1):23-34.
2Kandalaft LE, Chiang CL, Tanyi J, et al. A phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer[J]. J Transl Med, 2013, 11(1):149-162.
3Suso EMI, Dueland S, Rasmussen AM, et al. HTERT Mrna dendritic cell vaccination:complete response in a pancreatic cancer patient associated with reaponse against several Htert epitopes[J]. Cancer Immunol, Immun, 2011, 60(6):809-918.
4Shirwan H, Yolcu ES, Sharma RK, et al. The direct display of costimulatory proteins on tumor cells as a means of vaccination for cancer immunotherapy[J]. Methods Mol Biol, 2014, 1139:269-85.
5Yanofsky VR, Mitsui H, Felsen D, et al. Understanding dendritic cells and their role in cutaneous carcinoma and cancer immunotherapy[J]. Clin Dev Immunol, 2013:6241233.
6Brunekreeft KL, Strohm C, Gooden MJ, et al. Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death[J]. Mol Cancer, 2014, 13:85-98.
7Aranda F, Vacchelli E, Eggermont A, et al. Trial watch:peptide vaccines in cancer therapy[J].Oncoimmunology, 2013, 2(12):e26621.
8Zhang P, Yi SH, Li X, et al. Preparation of triple-negative breast cancer vaccine through electrofusion with day-3 dendritic cells[J]. PLoS One, 2014, 9(7):e102197.
10Koido S, Homma S, Okamoto M, et al. Improved immunogenicity of fusions between ethanol-treated cancer cells and dendritic cells exposed to dual TLR. stimulation[J]. OncoImmunology, 2013, 2(8):e25375.
